FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980497101> ?p ?o ?g. }

• W2980497101 abstract "X-linked hypophosphataemia (XLH) is a rare, genetic, chronically debilitating and deformative bone disease that profoundly impacts the affected individual’s day-to-day functioning and quality of life. High levels of circulating fibroblast growth factor 23 (FGF23) lead to excess urinary phosphate excretion and subsequent hypophosphataemia, resulting in defective bone mineralisation. Burosumab is an anti-FGF23 fully human monoclonal antibody, and the first treatment to target the underlying pathophysiology of XLH. Real world evidence has an important role in validating the findings of clinical studies and capturing clinically relevant outcomes. We report the initial experience of burosumab from one UK centre Evelina London Children’s Hospital (ELCH) participating in the burosumab early access program (EAP). Methods An EAP for burosumab was made available for children in the United Kingdom with XLH in 12 specialist centres. Inclusion criteria for the EAP included radiographic evidence of disease, XLH confirmed by genetic PHEX mutation, confirmed familial X-linked inheritance mutation or family history. Patients must have also had an unsatisfactory response to best available care and treatment. EAP enrolment was between January and March 2018. A total of 142 applications were received of which 135 were approved with 132 receiving treatment to date.1 Of the 7 declined, 4 failed to meet diagnostic criteria and 3 had insufficient radiological evidence.1 Treatment, including, dose was in accordance with the EMA marketing authorisation. Results Data are available on 9 ELCH patients who had completed the initial 12-week burosumab titration period and 7 patients with 24 week data. Mean age was 6.87 years (range 1.5-16.33 years (44% female)). The mean height and weight at week 0 was 105.7 cm (75-153 cm) and 20.92 kg (10.5-40.5 kg). Mean dose was 0.60 mg/kg at week 0 and 0.90 mg/kg at the end of the initial titration period at week 12 (0.91 mg/kg at week 24). Mean serum phosphorus was 0.67 mmol/L (0.5-0.8 mmol/L) in week 0 and 0.99 mmol/L at week 12 and 1.07 mmol/L at week 24 (0.9-1.3 mmol/L) representing a 60% increase in serum phosphorus levels at week 24. Mean serum ALP fell from 412.44 IU/L (269-495 IU/L) at week 0 to 364.44 IU/L at week 12 and 371.86 IU/L at week 24 (271-508 IU/L). 6MWT and TUG scores were available for 4 patients. A mean increase of 144.25 m (56%) was seen from 258 m at baseline to 402.25 by week 24. TUG scores increased by 32% from 5.74 (5.01-6.4) at baseline to 7.57 (5.39-11.43) by week 24. No patients had discontinued treatment to date due to adverse events.1Conclusions Early data from treating XLH patients with burosumab in a real-world UK setting from one centre demonstrates that key biochemical responses are in line with findings from the clinical study program. Improvements in clinically meaningful relevant outcomes such as 6MWT and TUG scores were also seen. References 1. Kyowa Kirin - data on file" @default.
• W2980497101 created "2019-10-25" @default.
• W2980497101 creator A5028584121 @default.
• W2980497101 creator A5044432480 @default.
• W2980497101 creator A5053728278 @default.
• W2980497101 creator A5064009073 @default.
• W2980497101 creator A5071952640 @default.
• W2980497101 date "2019-04-01" @default.
• W2980497101 modified "2023-10-16" @default.
• W2980497101 title "SUN-523 XLH Outcome Data from One Centre Experience with Burosumab" @default.
• W2980497101 doi "https://doi.org/10.1210/js.2019-sun-523" @default.
• W2980497101 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6553073" @default.
• W2980497101 hasPublicationYear "2019" @default.
• W2980497101 type Work @default.
• W2980497101 sameAs 2980497101 @default.
• W2980497101 citedByCount "1" @default.
• W2980497101 countsByYear W29804971012022 @default.
• W2980497101 crossrefType "journal-article" @default.
• W2980497101 hasAuthorship W2980497101A5028584121 @default.
• W2980497101 hasAuthorship W2980497101A5044432480 @default.
• W2980497101 hasAuthorship W2980497101A5053728278 @default.
• W2980497101 hasAuthorship W2980497101A5064009073 @default.
• W2980497101 hasAuthorship W2980497101A5071952640 @default.
• W2980497101 hasBestOaLocation W29804971011 @default.
• W2980497101 hasConcept C126322002 @default.
• W2980497101 hasConcept C141071460 @default.
• W2980497101 hasConcept C187212893 @default.
• W2980497101 hasConcept C190892606 @default.
• W2980497101 hasConcept C71924100 @default.
• W2980497101 hasConceptScore W2980497101C126322002 @default.
• W2980497101 hasConceptScore W2980497101C141071460 @default.
• W2980497101 hasConceptScore W2980497101C187212893 @default.
• W2980497101 hasConceptScore W2980497101C190892606 @default.
• W2980497101 hasConceptScore W2980497101C71924100 @default.
• W2980497101 hasIssue "Supplement_1" @default.
• W2980497101 hasLocation W29804971011 @default.
• W2980497101 hasLocation W29804971012 @default.
• W2980497101 hasOpenAccess W2980497101 @default.
• W2980497101 hasPrimaryLocation W29804971011 @default.
• W2980497101 hasRelatedWork W1506200166 @default.
• W2980497101 hasRelatedWork W1995515455 @default.
• W2980497101 hasRelatedWork W2048182022 @default.
• W2980497101 hasRelatedWork W2080531066 @default.
• W2980497101 hasRelatedWork W2604872355 @default.
• W2980497101 hasRelatedWork W2748952813 @default.
• W2980497101 hasRelatedWork W2899084033 @default.
• W2980497101 hasRelatedWork W3031052312 @default.
• W2980497101 hasRelatedWork W3032375762 @default.
• W2980497101 hasRelatedWork W3108674512 @default.
• W2980497101 hasVolume "3" @default.
• W2980497101 isParatext "false" @default.
• W2980497101 isRetracted "false" @default.
• W2980497101 magId "2980497101" @default.
• W2980497101 workType "article" @default.